1. Becker RC, et al. Lancet 2009;373:919-28

2. SCH
Becker RC, et al. Lancet 2009;373:919-28

3. Study profile
Becker RC, et al. Lancet 2009;373:919-28

4. Baseline characteristics and concomitant medication use
Becker RC, et al. Lancet 2009;373:919-28

5. Rate of bleeding events in the primary percutaneous coronary intervention cohort over 60 days of maintenance therapy
Becker RC, et al. Lancet 2009;373:919-28

6. Major secondary efficacy outcomes for primary percutaneous coronary intervention cohort over 60 days of maintenance therapy
Becker RC, et al. Lancet 2009;373:919-28

7. Rates (95% CI) of thrombolysis in myocardial infarction (TIMI) major and minor bleeding versus death or major adverse cardiac effects (MACE)
Rates (95% CI) of thrombolysis in myocardial infarction (TIMI) major and minor bleeding versus death or major adverse cardiac eff ects (MACE)
Thick lines are rates and thin lines are 95% CIs. The bottom shading is the 95% CI for the placebo rate of TIMI bleeding (3·3%, 95%CI 0–6·6). The top shading is the 95% CI for the placebo rate of death or MACE (8·6%, 4·0–13·2). The dark shading in the middle is the overlap of the two 95% CIs.
Becker RC, et al. Lancet 2009;373:919-28

8. Safety outcomes in patients receiving study drug who subsequently needed coronary artery bypass grafting
Becker RC, et al. Lancet 2009;373:919-28

9. Rate of bleeding events during 60 days of maintenance therapy in the secondary non-percutaneous coronary intervention cohort (treated medically)
Becker RC, et al. Lancet 2009;373:919-28

10. Proportion of patients with at least 80% inhibition of thrombin receptor agonist peptide (TRAP)-induced platelet aggregation
Becker RC, et al. Lancet 2009;373:919-28

11. Proportion of patients with at least 80% inhibition of thrombin receptor agonist peptide (TRAP)-induced platelet aggregation at 30 days and 60 days
Becker RC, et al. Lancet 2009;373:919-28